Buprenorphine HCL Transdermal Pen (3mL)
Buprenorphine HCL is a compounded formulation containing Buprenorphine HCL, prepared by Mixlab for veterinary use. Available by prescription.
A transdermal pen is a simple way to give your pet medicine through their skin—usually used for cats by applying gel to the inside of their ear.
Step-by-Step:
- Get the pen ready – Twist the pen to dispense a small amount of gel. If it’s your first time, you will need to “prime” it first (the gel should be flush with the edge of the tip)
- Wear gloves – Always use a disposable glove or finger cot so the medication doesn’t absorb into your skin.
- Twist to dose – Follow the pen’s directions (like two full twists) to get the right amount of gel out. Always click in a clockwise direction, clicking counter-clockwise will stop you
- Pick the spot – Apply to a hairless area, usually the inside of your cat’s ear. Make sure the area is clean and dry.
- Apply the gel – Dab the gel directly with the pen or use your gloved finger to rub it in gently. Avoid the ear canal.
- Let it dry – It usually dries in a minute or two. Try to keep your pet from rubbing it off.
- Recap the pen – This keeps the medication fresh.
- Wash your hands – Even if you wore gloves, wash thoroughly after.
- Reward your pet – A treat helps make it a stress-free routine!
- Store properly – Keep at room temp, away from sunlight. Track doses so you know when it’s time to refill.
Important: Only apply where your vet has directed—usually hairless areas. Never apply over fur or broken skin. Keep other pets from licking the area until it’s dry.
The uses and pharmacology described below reflect the FDA-approved labeling for this active ingredient; your veterinarian determines whether and how they apply to your animal's treatment plan.
Veterinarians most commonly consider buprenorphine hydrochloride in the context of acute pain management, particularly for perioperative care or following traumatic injury. It is frequently a point of discussion for feline patients because of its unique ability to be absorbed across the oral mucous membranes, providing a non-invasive administration route. By targeting specific receptors in the central nervous system, your veterinarian can manage the physiological signals associated with discomfort.
At a pharmacological level, buprenorphine acts as a partial mu-opioid receptor agonist and a kappa-opioid receptor antagonist. It possesses an extremely high affinity for the mu-receptor, which results in a long duration of action, even though it does not produce the same maximal effect as full agonists. Because it binds so tightly to these receptors, it can compete with and displace other medications from the same site. This high affinity also means the medication dissociates slowly from the receptor, contributing to its sustained influence on the patient’s comfort level. Your veterinarian will determine the clinical appropriateness of buprenorphine based on the severity of the anticipated discomfort and your pet’s overall health status.
Prescription only. Use only under the direction of a licensed veterinarian. This information is not a substitute for veterinary diagnosis, prescribing or monitoring. Compounded drugs are not approved by the FDA for safety or effectiveness.
Commonly observed effects following the administration of buprenorphine include sedation, localized digestive changes such as decreased appetite and behavioral shifts. In feline patients, veterinarians frequently observe mydriasis (dilated pupils) or localized euphoria, while canine patients may occasionally exhibit panting or mild respiratory depression. Owners should monitor for excessive lethargy or disorientation and contact their veterinarian promptly with any concerns.
This medication is typically used with extra caution or avoided in patients with known severe respiratory disease, head trauma or compromised hepatic function, as the liver is the primary site of metabolism for this prescription. Because buprenorphine binds so strongly to receptors, it may interfere with the effectiveness of other opioid medications if they are required simultaneously. Before starting a protocol, ensure your veterinarian has a complete history of all other medications your pet is receiving. Your veterinarian is the right person to provide guidance on the necessary duration of use and the most commonly considered monitoring schedule to ensure the management approach remains suitable for your pet's individual recovery needs.
Yes. Buprenorphine hydrochloride is a potent prescription medication and a controlled substance, meaning it can only be dispensed by a licensed pharmacy upon receipt of a valid authorization from a licensed veterinarian. Mixlab complies with all state and federal regulations regarding the dispensing of controlled medications.
Yes. While buprenorphine is available as a commercial injectable, Mixlab can compound it into customized strengths and alternative dosage forms, such as flavored oral liquids for transmucosal absorption, to suit the specific needs of your pet. The decision to use a compounded preparation rests with the prescribing veterinarian based on the clinical context.
Veterinarians often recommend transmucosal administration for cats because buprenorphine is absorbed very efficiently through the lining of the mouth directly into the bloodstream. This method is often preferred because it avoids the "first-pass" metabolism by the liver that occurs when a medication is swallowed, allowing for more commonly considered management of discomfort.
Sedation is a commonly observed effect of buprenorphine and most other opioid medications. While a degree of relaxation is often a clinical objective during recovery, you should report any signs of profound lethargy or difficulty waking up to your veterinarian immediately to ensure the dose remains appropriate for your pet.
